Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1D1 | P20393 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8061791 | 1.00 | NR1D1 (0.31) | NR1D1 | |
| SCHEMBL17449472 | 0.92 | — | — | |
| SCHEMBL8256157 | 0.84 | — | — | |
| SCHEMBL5957310 | 0.83 | CYP2D6 (0.33) | NR1D1 | |
| SCHEMBL6153982 | 0.81 | CPB2 (0.31) | — | |
| SCHEMBL12298229 | 0.79 | — | — | |
| SCHEMBL8090953 | 0.79 | ATM (0.39) | NR1D1 | |
| SCHEMBL8061701 | 0.79 | NR1D1 (0.31) | NR1D1 | |
| SCHEMBL14439275 | 0.79 | NR1D1 (0.31) | NR1D1 | |
| SCHEMBL19458 | 0.78 | TDP1 (0.42) | NR1D1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070185311-A1 | Peptide-Based Multimeric Targeted Contrast Agents | EPIX PHARMACEUTICALS, INC. (US) | 2007-08-09 | — | — | US | disclosed |
| EP-0731784-A1 | ARYL HALIDE SUBSTITUTED METALLIC COMPLEXES, PHARMACEUTICALS CONTAINING THESE COMPLEXES, THEIR USE FOR DIAGNOSTIC PURPOSES, AND METHODS FOR PREPARING THE COMPLEXES AND PHARMACEUTICALS | SCHERING AKTIENGESELLSCHAFT (DE) | 1996-09-18 | — | — | EP | disclosed |
| WO-1995015306-A1 | ARYL HALIDE SUBSTITUTED METALLIC COMPLEXES, PHARMACEUTICALS CONTAINING THESE COMPLEXES, THEIR USE FOR DIAGNOSTIC PURPOSES, AND METHODS FOR PREPARING THE COMPLEXES AND PHARMACEUTICALS | SCHERING AKTIENGESELLSCHAFT (DE) | 1995-06-08 | — | — | WO | disclosed |
| EP-0405704-B1 | DTPA-complexes derivatives, pharmaceutical compositions containing them, their use and process for their preparation | SCHERING AG (DE) | 1994-12-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185311-A1 | Peptide-Based Multimeric Targeted Contrast Agents | NGLY1, IAPP, NPPA | NR1D1 4108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.